The survival time of T‐ALL mice was prolonged in the Irf8+/+ group after FB23‐2 treatment, while the therapeutic effect was not apparent in mice in the Irf8−/− group (Figure 6H). This evidence concerns the gene IRF8 and acute lymphoblastic leukemia.